Cefuroxime Prophylaxis Is Effective in Noninstrumented Spine Surgery

Authors:
  • PFPatrick Francioli
    Patrick Francioli
  • SHStephan Harbarth
    Stephan Harbarth
  • LRLuca Regli
    Luca Regli
  • FPFrançois Porchet
    François Porchet
  • ARAlain Reverdin
    Alain Reverdin
  • BRBenedict Rilliet
    Benedict Rilliet
  • NTNicolas de Tribolet
    Nicolas de Tribolet
  • APAndré Pannatier
    André Pannatier
  • DPDidier Pittet
    Didier Pittet
  • GZGiorgio Zanetti
    Giorgio Zanetti

Abstract
Double-blind, placebo-controlled randomized clinical trial. To assess the efficacy of 1 preoperative 1.5 g dose of cefuroxime in preventing surgical site infection after surgery for herniated disc. Antibiotic prophylaxis was only tested in nonconclusive trials in this setting. The study was conducted in 2 university hospitals in Switzerland. Patients were assessed for occurrence of surgical site infection (defined by the criteria of the Centers for Diseases Control and Prevention), other infections, or adverse events up to 6 months after surgery. Outcome measures were compared in a univariate, per-protocol analysis. Baseline characteristics were similar in patients allocated to cefuroxime (n = 613) or placebo (n = 624). Eight (1.3%) patients in the cefuroxime group and 18 patients (2.8%) in the placebo group developed a surgical site infection (P = 0.073). A diagnosis of spondylodiscitis or epidural abscess was made in 9 patients in the placebo group, but none in the cefuroxime group (P < 0.01), which corresponded to a number necessary to treat of 69 patients to prevent one of these infections. There were no significant adverse events attributed to either cefuroxime or placebo. A single, preoperative dose of cefuroxime significantly reduces the risk of organ-space infection, most notably spondylodiscitis, after surgery for herniated disc.

This publication has 20 references indexed in Scilit: